First Patient Dosed in Ph 1 Study of CTX-8371 in Patients with Solid Tumors
“Dosing the first patient in the CTX-8371 Phase 1 represents the advancement of our third program into the clinic, which is an important milestone for the company,” said Vered Bisker-Leib, PhD, Chief Executive Officer. “We recently published preclinical data in the peer-reviewed journal, OncoImmunology, supporting the novel mechanism of action of CTX-8371: proteolytic cleavage and subsequent loss of cell surface PD-1. We believe this mechanism drives the enhanced anti-tumor activity of CTX-8371 in preclinical models when compared to approved anti-PD-1 and PD-L1 therapies and warrants its evaluation in patients.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome